Home » Clinical Trials » Sickle cell disease » NCT06565026
NCT06565026

An Open-Label Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CD34+ Human Hematopoietic Stem Cells Modified Using Transformer Base Editor in Participants With Severe Sickle Cell Disease

Study Summary

The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 injection in treating sickle cell disease.

Interested in this trial?

Submit an Inquiry

Interventions

CS-206GENETIC
Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique

Study Locations

FacilityCityStateCountry
The First Affiliated Hospital of Guangxi Medical UniversityNanningGuangxiChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: May 29, 2026